Oncology Venture har fått svar från FDA kring IND-ansökan och den föreslagna pivotala studien av LiPlaCis

NEXT STORY
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
PREV STORY
Vical and Brickell Announce Merger Agreement
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

author_avatar
NASDAQ Market News

AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020

author_avatar
NASDAQ Market News

Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)

SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory ...

author_avatar
NASDAQ Market News